Item 7.01. Regulation FD Disclosure.

On November 23, 2009, Salix Pharmaceuticals, Ltd. issued a press release announcing the close of its previously announced public offering of 5,500,000 shares of its common stock. Prior to the closing of the offering, Jefferies & Company, Inc., acting as the sole book-running manager of the offering, exercised in full its over-allotment option to purchase an additional 825,000 shares of Salix common stock. The exercise of this option increased the size of the offering to an aggregate of 6,325,000 shares of Salix common stock. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01. Other Events.

On November 23, 2009, Salix consummated the closing of its previously announced public offering of 5,500,000 shares of its common stock. Prior to the closing of the offering, Jefferies & Company, Inc., acting as the sole book-running manager of the offering, exercised in full its over-allotment option to purchase an additional 825,000 shares of Salix common stock. The exercise of this option increased the size of the offering to an aggregate of 6,325,000 shares of Salix common stock. Salix received proceeds, net of offering expenses and underwriting discounts and commissions, of approximately $128.2 million from the offering.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Press release dated November 23, 2009.

---